Skip to main
ZBH

ZBH Stock Forecast & Price Target

ZBH Analyst Ratings

Based on 20 analyst ratings
Hold
Strong Buy 15%
Buy 25%
Hold 50%
Sell 5%
Strong Sell 5%

Bulls say

Zimmer Biomet Holdings is a leading company in the orthopedic reconstructive market due to its extensive product portfolio and global market share. Despite challenges in its Foot & Ankle division and slower organic growth, the company continues to invest in new product development, which has improved its product vitality index. The company also has a strong balance sheet and has shown a commitment to returning capital to shareholders through share buybacks. While the current growth outlook may limit the stock's valuation, the potential for upside from improving end markets and successful integration of recent acquisitions make Zimmer Biomet a strong investment opportunity for long-term investors.

Bears say

Zimmer Biomet Holdings is facing challenges in meeting revenue and earnings expectations due to weaker organic growth and changes in the salesforce. Despite potential in new products and markets, the company's financial results have been average, and its stock is expected to trade at a P/E multiple of 10x in 2027. In addition, there are potential risks from slower markets, integration challenges, and competition in the orthopedic industry.

ZBH has been analyzed by 20 analysts, with a consensus rating of Hold. 15% of analysts recommend a Strong Buy, 25% recommend Buy, 50% suggest Holding, 5% advise Selling, and 5% predict a Strong Sell.

This aggregate rating is based on analysts' research of Zimmer Biomet Hlds and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Zimmer Biomet Hlds (ZBH) Forecast

Analysts have given ZBH a Hold based on their latest research and market trends.

According to 20 analysts, ZBH has a Hold consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $102.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $102.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Zimmer Biomet Hlds (ZBH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.